Stoke Therapeutics, Inc. (STOK) Stock

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. (STOK) stock trades at $25.04 with a market capitalization of $1.62B. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.74, reflecting a net loss over the last twelve months, price-to-book of 4.97, price-to-sales of 60.81. Over the past 52 weeks the stock has ranged between $20.32 and $40.22, and currently trades 37.7% below its 52-week high.

On profitability, Stoke Therapeutics, Inc. generates a return on equity (ROE) of -59.36% (negative, reflecting a net loss), return on capital employed of -63.45%, an operating margin of -5.77%, a net profit margin of -753.60%.

Stoke Therapeutics, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Stoke Therapeutics, Inc. reported revenue of $0 rising to $184.0M. Compounded, revenue has grown —% a year over five years, 148.4% over three, 397.3% over the last twelve months. Net profit fell to $-7.0M.

The most recent net margin is -753.60%. On a trailing twelve-month basis to Jun '26, revenue is $27.0M and net profit $-208.0M.

Borrowings held roughly flat from $3.0M to $3.0M, cash from operations was $46.0M in the latest year, positive in 1 of the last 9.

Return on equity has averaged -40.1% over five years, and was -2.0% in the most recent year.

The share price itself has compounded at -0.5% a year over five years, 41.6% over three, 236.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Stoke Therapeutics, Inc. (STOK) — frequently asked questions